MeSH D002822 - choriocarcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Bleomycin | Bleomycin | 1996-06-01 | |||
| Cipla | Bleomycin | Bleomycin | 2019-03-11 | |||
| Hospira | Bleomycin | Bleomycin | 2000-03-10 | |||
| Methotrexate | Methotrexate | 1982-01-01 | ||||
| Bristol Myers Squibb | Bleomycin | Blenoxane | 1982-01-01 | |||
| Methotrexate | Mexate | 1982-01-01 | ||||
| Methotrexate | Mexate-aq | 1985-02-14 | ||||
| Methotrexate | Mexate-aq Preserved | 1989-04-14 | ||||
| Hikma Pharmaceuticals | Bleomycin | Bleomycin | 2001-10-17 | |||
| Dactinomycin | Dactinomycin | 2010-03-16 | ||||
| Methotrexate | Methotrexate | 1994-08-01 | ||||
| Recordati | Dactinomycin | Cosmegen | 1982-01-01 | |||
| Eugia Pharma Specialties | Dactinomycin | Dactinomycin | 2017-11-09 | |||
| Methotrexate | Methotrexate | 2012-03-29 | ||||
| Fresenius Kabi | Bleomycin | Bleomycin | 2008-01-28 | |||
| Methotrexate | Methotrexate | 1999-02-26 | ||||
| XGen Pharmaceuticals | Dactinomycin | Dactinomycin | 2019-05-20 |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
23%3/13
Phase 3
33%7/21
Approved: 5Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use